Claudia Vasallo

Claudia Vasallo

Auto-generated profile, based on publicly available information

Claudia Vasallo

Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2019 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
RDRamon Diaz-Uriarte
Ramon Diaz-Uriarte
CVClaudia Vasallo
Claudia Vasallo
Successful prediction of the likely paths of tumor progression is valuable for diagnostic, prognostic, and treatment purposes. Cancer progression models (CPMs) use cross-sectional samples to identify restrictions in the order of accumulation of driver mutations and thus CPMs encode the paths of tumor progression. Here we analyze the performance of four CPMs to examine whether they can be used to predict the true distribution of paths of tumor progression and to estimate evolutionary unpredictability. Employing simulations we show that if fitness landscapes are single peaked (have a single fitness maximum) there is good agreement between true and predicted distributions of paths of tumor progression when sample sizes are large, but performance is poor with the currently common much smaller sample sizes. Under multi-peaked fitness landscapes (i.e., those with multiple fitness maxima), performance is poor and improves only slightly with sample size. In all cases, detection regime (when tumors are sampled) is a key determinant of performance. Estimates of evolutionary unpredictability from the best performing CPM, among the four examined, tend to overestimate the true unpredictability and the bias is affected by detection regime; CPMs could be useful for estimating upper bounds to the true evolutionary unpredictability. Analysis of twenty-two cancer data sets shows low evolutionary unpredictability for several of the data sets. But most of the predictions of paths of tumor progression are very unreliable, and unreliability increases with the number of features analyzed. Our results indicate that CPMs could be valuable tools for predicting cancer progression but that, currently, obtaining useful predictions of paths of tumor progression from CPMs is dubious, and emphasize the need for methodological work that can account for the probably multi-peaked fitness landscapes in cancer. Knowing the likely paths of tumor progression is instrumental for cancer precision medicine as it would allow us to identify genetic targets that block disease progression and to improve therapeutic decisions. Direct information about paths of tumor progression is scarce, but cancer progression models (CPMs), which use as input cross-sectional data on genetic alterations, can be used to predict these paths. CPMs, however, make assumptions about fitness landscapes (genotype-fitness maps) that might not be met in cancer. We examine if four CPMs can be used to predict successfully the distribution of tumor progression paths; we find that some CPMs work well when sample sizes are large and fitness landscapes have a single fitness maximum, but in fitness landscapes with multiple fitness maxima prediction is poor. However, the best performing CPM in our study could be used to estimate evolutionary unpredictability. When we apply the best performing CPM in our study to twenty-two cancer data sets we find that predictions are generally unreliable but that some cancer data sets show low unpredictability. Our results highlight that CPMs could be valuable tools for predicting disease progression, but emphasize the need for methodological work to account for multi-peaked fitness landscapes.

8 April 2022 in Human Mutation
Verified
Journal Article
Open access
JRJordi Rambla
Jordi Rambla
MBMichael Baudis
Michael Baudis
RARoberto Ariosa
Roberto Ariosa
TBTim Beck
Tim Beck
LFLauren A. Fromont
Lauren A. Fromont
ABAnthony J. Brookes
Anthony J. Brookes
Beacon is a basic data discovery protocol issued by the Global Alliance for Genomics and Health (GA4GH). The main goal addressed by version 1 of the Beacon protocol was to test the feasibility of broadly sharing human genomic data, through providing simple “yes” or “no” responses to queries about the presence of a given variant in datasets hosted by Beacon providers. The popularity of this concept has fostered the design of a version 2, that better serves real‐world requirements and addresses the needs of clinical genomics research and healthcare, as assessed by several contributing projects and organizations. Particularly, rare disease genetics and cancer research will benefit from new case level and genomic variant level requests and the enabling of richer phenotype and clinical queries as well as support for fuzzy searches. Beacon is designed as a “lingua franca” to bridge data collections hosted in software solutions with different and rich interfaces. Beacon version 2 works alongside popular standards like Phenopackets, OMOP, or FHIR, allowing implementing consortia to return matches in beacon responses and provide a handover to their preferred data exchange format. The protocol is being explored by other research domains and is being tested in several international projects.

1 November 2015 in Virus Research
Verified
Journal Article
Closed access
CVClaudia Vasallo
Claudia Vasallo
PGPablo Gastaminza
Pablo Gastaminza

20 June 2025 in medRxiv
Verified
Preprint
Open access
PDF file
EBEva Brigos-Barril
Eva Brigos-Barril
CVClaudia Vasallo
Claudia Vasallo
XFXavier Farré
Xavier Farré
CMCarlos Morcillo-Suárez
Carlos Morcillo-Suárez
SPSara Polo-Alonso
Sara Polo-Alonso
GMGerard Muntane
Gerard Muntane
The persistence of genetic variants that increase susceptibility to complex diseases poses an evolutionary paradox: despite their detrimental health effects, these variants are not eliminated by natural selection. Life-history theory proposes that trade-offs and pleiotropic effects across fitness components may explain the evolutionary maintenance of disease-associated alleles. We hypothesize that certain disease-risk alleles might segregate in the population because they confer reproductive advantages, even at the expense of late-life costs on health and longevity. Leveraging genome-wide association studies, we investigated genetic correlations and pleiotropic relationships between 62 complex diseases, longevity, and fertility. In our study, we estimated fertility by meta-analyzing complementary measures of offspring number and used parental lifespan as a proxy for longevity. We found that 85% of diseases showed negative genetic correlations with longevity, whereas 87% of diseases with significant correlations showed positive associations with fertility. Moreover, most disease-risk variants were associated with reduced longevity, even after accounting for socioeconomic confounders. Fertility-increasing alleles exhibited evolutionary signals consistent with adaptive selection despite having pleiotropic effects on disease-risk. Finally, we compared the number of offspring among individuals with high genetic risk of disease and found that, for most diseases, affected individuals had more offspring than disease-free individuals. However, for early-onset conditions, non-affected individuals exhibited higher fertility, highlighting the reproductive cost of early-onset diseases. These findings support the Antagonistic Pleiotropy theory, showing that alleles that enhance early-life reproductive success can persist despite late-life health costs. By uncovering these evolutionary trade-offs between reproduction, longevity, and disease risk, our study shows how Darwinian selection continues to shape contemporary patterns of human disease susceptibility. Understanding these evolutionary trade-offs can inform public health approaches and help anticipate unintended consequences of targeting disease-related genetic pathways.